Additionally, immunohistochemical results of study in vivo further confirmed that FGFC1 suppressed erlotinib-resistant NSCLC xenograft tumor growth through decreasing p-EGFR and Ki67 expression. The gene discussed is EGFR; the disease is neoplasm.